ranolazine sold brand name ranexa among others medication used treat heart related chest typically used together medications benefits appear smaller women taken common side effects include constipation headache nausea serious side effects may include qt use recommended liver works clear may involve adenosine ranolazine approved medical use united states commonly prescribed medication united states million ranolazine used treat chronic may used concomitantly Î² blockers nitrates calcium channel blockers antiplatelet therapy lipidlowering therapy ace inhibitors angiotensin receptor also effective preventing atrial fibrillation studied monotherapy well combination medications used treat irregular use recommended scotland contraindications ranolazine related metabolism described drug interactions additionally clinical trials ranolazine slightly increased qt interval fda label contains warning doctors beware effect drugs effect qt interval increased setting liver dysfunction thus contraindicated persons mild severe liver common side effects dizziness constipation side effects include headache ranolazine metabolized mainly enzyme also inhibits another metabolizing enzyme cytochrome reason doses ranolazine drugs interact enzymes need adjusted used patient ranolazine used drugs ketoconazole clarithromycin nelfinavir strongly inhibit drugs activate rifampin drugs moderate inhibitors diltiazem verapamil erythromycin dose ranolazine drugs metabolized tricyclic antidepressants may need given reduced doses administered ranolazine inhibits persistent late inward sodium current ina heart variety voltagegated sodium inhibiting current leads reductions intracellular calcium levels turn leads reduced tension heart wall leading reduced oxygen requirements qt prolongation effect ranolazine surface electrocardiogram result inhibition ikr prolongs ventricular action ranolazine also exhibits effects delayed rectifier current hergikr potassium channels readily stimulates myogenesis reduces prooxidant inflammationoxidative condition activates calcium signaling ranolazine prolongs action potential duration corresponding qt interval prolongation electrocardiography blocks ina current prevents calcium overload caused hyperactive ina current thus stabilizes membrane reducing syntex inc originally began developing ranolazine studies completed afterwards phase studies done however found formulation result adequate plasma concentrations drug due sustainedrelease sr formulation ranolazine roche acquired syntex cv therapeutics licensed north american european rights ranolazine syntex subsidiary roche discovered drug developed phase ii trials cv therapeutics acquired remaining worldwide rights ranolazine cv therapeutics exclusively licensed rights ranolazine europe countries gilead acquired cv gilead expanded partnership menarini include additional countries including ranolazine approved fda january treatment patients chronic angina secondline treatment addition label updated make ranolazine firstline treatment alone april ranolazine approved european emea use ranolazine manufactured sold ranexa gilead according gilead annual income statement combined sales ranexa another gilead product ambisom million fourth quarter ranolazine might constitute therapeutic option improve two main strategies currently used treat metastatic research suggests transfer neurotransmitter one type skin cell melanocytes another keratinocytes altered electrical activity promoted melanoma initiation preclinical httpsenwikipediaorgwikiranolazine